Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
The purpose of this study is to explore the efficacy and safety of chidamide combined with etoposide and cisplatin/carboplatin in the first-line treatment of advanced extrapulmonary neuroendocrine carcinoma.
Neuroendocrine Tumors|Neuroendocrine Carcinoma
DRUG: Chidamide|DRUG: Etoposide + Cisplatin/Carboplatin
Objective Response Rate (ORR), Percentage of participants with complete response and partial response, assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, Up to 2 years
Disease Control Rate (DCR), Percentage of participants with complete response, partial response, and stable disease assessed by the investigators according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, Up to 2 years|Progression-free Survival (PFS), Time from the date of enrollment until progression or death, whichever is first met, Time from the date of enrollment to the earliest of documented disease progression or death, assessed up to 2 years|Overall Survival (OS), Time from the date of enrollment until death, Time from the date of enrollment to the earliest of documented death, assessed up to 3 years|Treatment-related Adverse Events (Safety), Frequency and grade of adverse events (the grade of adverse events is assessed according to CTCAE v4.03)., Up to 2 years
This study is a single-arm, multi-center, two-stage, phase II clinical trial conducted in China. This study adopts Simon's two-stage design, and the inclusion criteria and exclusion criteria of the two stages were consistent. Twelve patients with extrapulmonary neuroendocrine carcinoma will be enrolled in the first stage. If more than four complete or partial responses were seen at planned interim analysis, the additional 16 patients will be recruited in the second stage and a total of 28 patients will be treated.